EMA — authorised 31 December 2009
- Application: EMEA/H/C/000753
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Local brand name: Arxxant
- Status: withdrawn
🇪🇺 RUBOXISTAURIN in European Union
EMA authorised RUBOXISTAURIN on 31 December 2009
Marketing authorisation
RUBOXISTAURIN in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in European Union
Frequently asked questions
Is RUBOXISTAURIN approved in European Union?
Yes. EMA authorised it on 31 December 2009.
Who is the marketing authorisation holder for RUBOXISTAURIN in European Union?
Eli Lilly Nederland B.V. holds the EU marketing authorisation.